HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
21621859
DOI
10.1016/j.jneuroim.2011.04.011
PII: S0165-5728(11)00126-3
Knihovny.cz E-zdroje
- MeSH
- demyelinizační nemoci farmakoterapie imunologie patologie MeSH
- dospělí MeSH
- HLA-DR antigeny biosyntéza MeSH
- HLA-DRB1 řetězec MeSH
- interferon beta aplikace a dávkování terapeutické užití MeSH
- jednonukleotidový polymorfismus genetika MeSH
- lidé středního věku MeSH
- lidé MeSH
- longitudinální studie MeSH
- magnetická rezonanční tomografie MeSH
- mladiství MeSH
- mladý dospělý MeSH
- následné studie MeSH
- prospektivní studie MeSH
- roztroušená skleróza farmakoterapie imunologie patologie MeSH
- zánět farmakoterapie imunologie patologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Research Support, U.S. Gov't, Non-P.H.S. MeSH
- srovnávací studie MeSH
- Názvy látek
- HLA-DR antigeny MeSH
- HLA-DRB1 řetězec MeSH
- HLA-DRB1*15:01 antigen MeSH Prohlížeč
- interferon beta MeSH
OBJECTIVES: The presence of MRI lesions at the first demyelinating event increases the risk of developing clinically definite multiple sclerosis (MS). The HLA DRB1*1501 genotype is linked to MS susceptibility but its relationship to quantitative MRI parameters at the first demyelinating event has not been assessed. The objectives were to assess the associations between HLA DRB1*1501 status and magnetic resonance imaging (MRI) measures in clinically isolated syndromes (CIS) at the first demyelinating event. METHODS: We genotyped 205 CIS patients (age: 29.0±7.7 years) enrolled in the Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET study), a multi-center, clinical study of CIS for rs3135005, a single nucleotide polymorphism associated with HLA DRB1*1501 status. The inclusion criteria required 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. Clinical and MRI assessments were obtained within 4 months of the initial demyelinating event. RESULTS: The frequency of HLA DRB1*1501 positivity was 102/205 (49.7%). HLA DRB1*1501 positivity was associated with higher contrast-enhancing (CE) lesion number (p=0.002), higher CE-lesion volume (LV) (p<0.001) and exhibited a trend with higher T2-LV (p=0.012). There was no evidence for significant associations of HLA DRB1*1501 positivity with disability, symptoms at CIS presentation, whole brain, white and gray matter atrophy. CONCLUSIONS: HLA DRB1*1501 positivity is associated with increased brain inflammatory processes at first clinical onset. However, the effect sizes of the HLA DRB1*1501 associations with MRI are modest, which potentially limits the clinical usefulness.
Citace poskytuje Crossref.org